Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion

被引:599
作者
Baxter, MA
Wynn, RF
Jowitt, SN
Wraith, JE
Fairbairn, LJ
Bellantuono, I [1 ]
机构
[1] Royal Manchester Childrens Hosp, Giving Living Postgrad Ctr, Stem Cell Res Grp, Manchester M27 4HA, Lancs, England
[2] Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England
[3] Royal Manchester Childrens Hosp, Willink Biochem Genet Unit, Manchester M27 1HA, Lancs, England
[4] Christie Hosp, Paterson Inst Canc Res, Canc Res UK Gene Therapy Grp, Manchester, Lancs, England
关键词
mesenchymal stem cells; transplantation;
D O I
10.1634/stemcells.22-5-675
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Human marrow stromal cells (MSCs) can be isolated from bone marrow and differentiate into multiple tissues in vitro and in vivo. These properties make them promising tools in cell and gene therapy. The lack of a specific MSC marker and the low frequency of MSCs in bone marrow necessitate their isolation by in vitro expansion prior to clinical use. This may severely reduce MSC proliferative capacity to the point that the residual proliferative potential is insufficient to maintain long-term tissue regeneration upon reinfusion. In this study we determined the effect of in vitro expansion on the replicative capacity of MSCs by correlating their rate of telomere loss during in vitro expansion with their behavior in vivo. We report that even protocols that involve minimal expansion induce a rapid aging of MSCs, with losses equivalent to about half their total replicative lifespan.
引用
收藏
页码:675 / 682
页数:8
相关论文
共 41 条
  • [1] EVIDENCE FOR A CRITICAL TELOMERE LENGTH IN SENESCENT HUMAN FIBROBLASTS
    ALLSOPP, RC
    HARLEY, CB
    [J]. EXPERIMENTAL CELL RESEARCH, 1995, 219 (01) : 130 - 136
  • [2] Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy
    Banfi, A
    Muraglia, A
    Dozin, B
    Mastrogiacomo, M
    Cancedda, R
    Quarto, R
    [J]. EXPERIMENTAL HEMATOLOGY, 2000, 28 (06) : 707 - 715
  • [3] The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105)
    Barry, FP
    Boynton, RE
    Haynesworth, S
    Murphy, JM
    Zaia, J
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 265 (01) : 134 - 139
  • [4] Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo
    Bartholomew, A
    Patil, S
    Mackay, A
    Nelson, M
    Buyaner, D
    Hardy, W
    Mosca, J
    Sturgeon, C
    Siatskas, M
    Mahmud, N
    Ferrer, K
    Deans, R
    Moseley, A
    Hoffman, R
    Devine, SM
    [J]. HUMAN GENE THERAPY, 2001, 12 (12) : 1527 - 1541
  • [5] Retrovirally mediated correction of bone marrow-derived mesenchymal stem cells from patients with mucopolysaccharidosis type I
    Baxter, MA
    Wynn, RF
    Deakin, JA
    Bellantuono, I
    Edington, KG
    Cooper, A
    Besley, GTN
    Church, HJ
    Wraith, JE
    Carr, TF
    Fairbairn, LJ
    [J]. BLOOD, 2002, 99 (05) : 1857 - 1859
  • [6] Bayliss High OB, 1996, THEORY PRACTICE HIST, P213
  • [7] Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2
    Bianchi, G
    Banfi, A
    Mastrogiacomo, M
    Notaro, R
    Luzzatto, L
    Cancedda, R
    Quarto, R
    [J]. EXPERIMENTAL CELL RESEARCH, 2003, 287 (01) : 98 - 105
  • [8] Switching and signaling at the telomere
    Blackburn, EH
    [J]. CELL, 2001, 106 (06) : 661 - 673
  • [9] Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO
  • [10] 2-F